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Amyloidosis: A Clinical OverviewBouke P.C. Hazenberg, MD, PhDKEYWORDS
 Systemic amyloidosis  Amyloid fibril  Protein misfolding  Precursor protein
 Typing  Diagnosis  Treatment  Disease monitoring
KEY POINTS
 Amyloidosis is the name for some diseases caused by protein misfolding; 30 different
soluble precursor proteins can aggregate and be deposited as insoluble amyloid fibrils.
 Amyloid deposition is localized or systemic; the 4 main types of systemic amyloidosis are
AL (light chain), AA (inflammation), ATTR (hereditary and old age), and Ab2M (dialysis).
 Clinical management comprises proof of amyloid, systemic evidence, reliable typing,
precursor assessment, severity of organ disease, choice of treatment, and planned
follow-up.
 The precursor-product concept is the current basis of treatment, thereby aiming to
decrease the levels of precursor proteins in serum to normal or undetectable values.
Future clinical research will be directed at stopping amyloid deposition and increasing
amyloid clearance.
 Protein misfolding is not only a characteristic of amyloidosis; it is also involved in many
other disabling cardiac and neurologic degenerative diseases that interfere with healthy
aging.INTRODUCTION
The description of the autopsy of a young man in 1639 by Nicolaes Fonteyn, a Dutch
physician and poet who lived in Amsterdam, was probably the first report of a patient
with systemic amyloidosis. Since then, lardaceous changes in enlarged organs, such
as the liver, spleen, heart, and kidneys, have drawn the attention of pathologists such
as Rokitansky. In 1854, Rudolph Virchow was one of the first to use the term amyloid
for this amorphous and hyaline change in tissue because of an iodine-staining reaction
similar to that of starch (amylon; Greek for origin). Although it is now known that
amyloid has nothing to do with starch, the term amyloid is still in use today. BennholdFunding Sources: None.
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Hazenberg324introduced Congo Red staining in 1922 as a useful method to identify amyloid in tissue
specimens. In 1927, Divry and Florkin described the characteristic green birefringence
when Congo Red-stained amyloid was viewed under polarized light. In 1959, Cohen
and Calkins detected the fibril nature of amyloid when viewed under the electron
microscope.1
Amyloidosis is the name for 30 protein-folding diseases (Table 1), all characterized
by extracellular deposition of a specific soluble precursor protein that aggregates
in the form of insoluble fibrils. These rigid and unbranching fibrils, approximately
10 nm in diameter, are characterized by a molecular b-pleated sheet structure that
is usually composed of peptides arranged in an antiparallel configuration. This struc-
ture of the fibrils is responsible for its insolubility, resistance to proteolysis, and binding
affinity for Congo Red dye that shows a characteristic green birefringence when
viewed under polarized light (Fig. 1).2
The aim of this article is to present a clinical overview of the different types of
amyloidosis, disease manifestations, patient management, diagnosis, imaging tech-
niques, treatment, and follow-up.
AMYLOID STRUCTURE AND PATHOGENESIS
Amyloidoses are protein-misfolding diseases in which small (parts of) proteins of
about 10 to 15 kDa acquire an alternative and relatively misfolded state at minimum
energy and subsequently aggregate into oligomers and polymers. Three mechanisms
seem to operate independently or in combination: the precursor protein may have an
intrinsic propensity to misfold that becomes evident with aging (wild-type transthyre-
tin) or as high serum levels (serum amyloid A protein and immunoglobulin free light
chains); a hereditary acquired mutated protein (transthyretin); and proteolytic remod-
eling of the precursor protein (b-amyloid precursor protein). Interaction with the extra-
cellular matrix also seems to be important and may be related to preferential
deposition of amyloid in some organs or tissues.3
Extracellular deposition of amyloid fibrils in organs and tissues results in tissue infil-
tration and swelling leading to progressive loss of function of the affected organ. Some-
times toxic effects, believed to be caused by toxic oligomers, have been observed (eg,
in cerebral amyloid). These oligomers are nonfibrillar intermediate aggregates that are
formed early in the process of fibril formation. Another constituent of all amyloid is
serum amyloid P component (SAP), a glycoprotein that belongs to the pentraxin family
and binds to all types of amyloid in a calcium-dependent way. SAP is highly protected
against proteolysis and thusmakes amyloid fibrils resistant to degradation. Apolipopro-
tein E is also a constituent of amyloid. Glycosaminoglycans (eg, heparan sulfate) are
found in all types of amyloid and interact with extracellular matrix components such
as laminin, entactin, and collagen IV. This interaction probably constitutes a scaffold
that facilitates the initial phase of fibril nucleation and could have a targeting role in
the localization of amyloid deposits in tissue.3
TYPES OF AMYLOIDOSIS
Deposition of amyloid is localized (ie, fibrils produced in and limited to 1 organ or site of
the body) or systemic (ie, fibril deposition in various organs and tissues throughout the
body). The current classification of amyloidosis (see Table 1) is based on the chemical
characterization of the precursor protein.2,4
Organ-specific localized amyloidosis can be found in Alzheimer disease (b-protein
in the plaques) and diabetes mellitus type 2 (amylin in the islands of Langerhans).
The pathogenic role of amyloid deposition in these diseases is unclear.4 Nodular
Table 1









S, L A All organs except CNS
AH Immunoglobulin heavy
chain
S, L A All organs except CNS
Ab2M b2-microglobulin, wild
type
S A Musculoskeletal system
b2-microglobulin, variant S H ANS
ATTR Transthyretin, wild type S, L A Heart mainly in men,
tenosynovium
Transthyretin, variants S H PNS, ANS, heart, eye,
leptomeninges
AA (Apo) serum amyloid A S A All organs except CNS
AApoAI Apolipoprotein A I,
variants





AApoAII Apolipoprotein A II,
variants
S H Kidney
AApoAIV Apolipoprotein A IV,
wild type
S A Kidney medulla and
systemic
AGel Gelsolin, variants S H PNS, cornea
ALys Lysozyme, variants S H Kidney
ALect2 Leukocyte chemotactic
factor-2
S A Kidney, primarily
AFib Fibrinogen a, variants S H Kidney, primarily
ACys Cystatin C, variants S H PNS, skin
ABri ABriPP, variants S H CNS
ADana ADanPP, variants L H CNS






APrP Prion protein, wild type L A CJD, fatal insomnia
Prion protein, variants L H CJD, GSS syndrome, fatal
insomnia
ACal (Pro)calcitonin L A C-cell thyroid tumors
AIAPP Islet amyloid
polypeptideb
L A Islets of Langerhans,
insulinomas
AANF Atrial natriuretic factor L A Cardiac atria
APro Prolactin L A Pituitary prolactinomas,
aging pituitary
AIns Insulin L A Iatrogenic, local injection
ASPC Lung surfactant protein L A Lung
AGal7 Galectin 7 L A Skin
ACor Corneodesmin L A Cornified epithelia, hair
follicles










AMed Lactadherin L A Senile aortic, media
AKer Kerato-epithelin L A Cornea, hereditary
ALac Lactoferrin L A Cornea
AOaap Odontogenic ameloblast-
associated protein
L A Odontogenic tumors
ASem1 Semenogelin 1 L A Vesicula seminalis
Abbreviations: ANS, autonomic nervous system; CJD, Creutzfeldt-Jakob disease; CNS, central
nervous system; GSS, Gerstmann-Straussler-Scheinker syndrome; PNS, peripheral nervous system.
a ADan is the product of the same gene as Abri.
b Also called amylin.
Data from Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2012
recommendations from the Nomenclature Committee of the International Society of Amyloidosis.
Amyloid 2012;19:167–70.
Hazenberg326localized amyloid is an incidental finding and can be present in the skin (not only
nodular but also macular amyloid and lichen amyloidosis), eyelid, conjunctiva, breast,
larynx, bronchial tree, lung, and genitourinary tract. In most cases, low numbers of
clonal plasma cells can be detected in the biopsy sample. Surgery is usually the treat-
ment of choice. Local recurrence is frequent and can again be treated surgically.5
Localized nodular skin amyloidosis is sometimes associated with Sjo¨gren disease.6
In contrast to localized amyloidosis, systemic amyloidosis leads to serious signs
and symptoms caused by progressive disease in organs and tissues. There are
many types of systemic amyloidosis (see Table 1), but 4 types are seen most
frequently: AL, AA, ATTR, and Ab2M amyloidosis.
4
AL amyloidosis is the most common type. This disease is caused by a clonal plasma
cell dyscrasia; it often occurs as low-grade clonal disease, sometimes multiple
myeloma, and rarely non-Hodgkin lymphoma or Waldenstro¨m disease. The precursor
of this type of amyloid is either lambda or kappa immunoglobulin free light chain. Clin-
ical manifestations are diverse, such as cardiomyopathy, nephrotic syndrome, renal
failure, hepatomegaly, splenomegaly, orthostatic hypotension, diarrhea, intestinalFig. 1. A sample of abdominal subcutaneous fat aspirate containing amyloid deposits,
stained with Congo Red. (A) Viewed in normal light, amyloid is stained red. Bar length is
100 mm. (B) Viewed in polarized light, amyloid shows apple-green birefringence (collagen
is bluish-gray).
Amyloidosis 327pseudoobstruction, peripheral neuropathy, autonomic neuropathy, arthropathy, carpal
tunnel syndrome (CTS), bleeding, adrenal dysfunction, goiter, pulmonary problems,
weight loss, fatigue, malaise, and glossomegaly.7
The second most common type is AA amyloidosis. This disease is caused by long-
standing inflammation, such as rheumatoid arthritis, inflammatory bowel disease,
chronic infections (eg, tuberculosis, osteomyelitis, leprosy), and hereditary autoinflam-
matory diseases (eg, familial Mediterranean fever, also called FMF). The precursor of
this type is the HDL3-associated apolipoprotein serum amyloid A protein (SAA), an
acute phase reactant. Signs of kidney disease, such as proteinuria (progressing to
nephrotic syndrome) and loss of renal function (progressing to renal failure), are
observed most frequently (in about 90% of cases), followed at a distance by auto-
nomic neuropathy, bowel involvement, splenomegaly, hepatomegaly, goiter, and
cardiomyopathy.8,9
The third most common type is ATTR amyloidosis. The familial form of this disease is
caused by many autosomal dominantly inherited point mutations of the precursor
protein transthyretin (TTR). Transthyretin is an acronym for the transport protein of
thyroid hormone and retinol-binding protein. About 100 of these TTR mutations have
been described, but most common is the TTR-Met30 mutation. Clinical manifestations
are predominantly peripheral and autonomic neuropathy, but also cardiomyopathy,
renal failure, and eye involvement (vitreous opacities) are frequently observed. Some-
times a severe cardiomyopathy is the initial presentation of the disease.10 There is also
a nonfamilial acquired form of ATTR amyloidosis. In this disease of old-aged men
(rarely women), nonmutated (wild-type) TTR can also act as an amyloid precursor by
a still unknown mechanism. This wild-type ATTR amyloidosis (formerly called senile
systemic amyloidosis) is characterized by a slowly progressive cardiomyopathy,
frequently associated with CTS, but without other neuropathy.11
The fourth type is Ab2M amyloidosis. This disease is caused by end-stage renal
disease in which highly increased serum levels of b2-microglobulin persist for years
because b2-microglobulin is not effectively cleared by dialysis. The disease is charac-
terized by high serum levels of b2-microglobulin and posttranslational modifications to
be deposited as amyloid fibrils in predominantly osteoarticular tissues. CTS and
shoulder pain are among the first manifestations, followed by large periarticular cysts
and sometimes by pathologic fractures, or a destructive spondylarthropathy.12,13
Recently, a hereditary Ab2M amyloidosis has been described, characterized by auto-
nomic neuropathy and slowly progressive gastrointestinal symptoms.14
Other types of systemic amyloidosis are rare.15 However, in patients without a family
history of amyloid disease, a hereditary type of amyloidosis may be present.16 In
patients with almost exclusive kidney disease, other types should be considered,
such as fibrinogen a,17 lysozyme,18 apolipoprotein A I, apolipoprotein A II, apolipopro-
tein A IV, and the recently described leukocyte chemotactic factor-2.19 In patients with
almost exclusive cardiac or neuropathic disease, the apolipoprotein A I type should
not be overlooked. In patients with hepatic amyloid, the lysozyme and apolipoprotein
A I type can be present. Apolipoprotein A I can be present in the skin and larynx. Gel-
solin is typically found in lattice corneal dystrophy.20EPIDEMIOLOGY
Even in developed countries, few incidence data have been collected systemati-
cally.21 The data from 1 study about the incidence of AL amyloidosis in Olmsted
County, Minnesota, are still used. In this study, the overall age-adjusted and sex-
adjusted 95% confidence interval was 5.1 to 12.8 per million patients per year.22 In
Hazenberg328a recent Swedish study, the estimated incidence of AL amyloidosis was 3.2 per million
per year and AA amyloidosis 2.0 per million per year.23 The median age for AL and AA
amyloidosis is between 55 and 60 years.24 The prognosis of untreated patients is poor,
as noticed in older studies; median survival was 6 to 12 months for AL amyloidosis and
3 to 4 years for AA amyloidosis.24 The estimated median survival of untreated patients
with hereditary ATTR amyloidosis is almost 10 years, although some patients may
survive up to 15 years. An estimate of mortality is that 0.5 to 1.0 per 1000 persons
die in the United Kingdom because of AL amyloidosis.25 In most studies of patients
with the AL type, the proportion of men is somewhat higher (about 1.1–1.3) than
women. The reverse (more women than men) is observed for AA amyloidosis because
of the high proportion of patients (mainly women) with underlying rheumatoid arthritis.
In developing countries, the prevalence of AA amyloidosis is higher than AL amyloid-
osis because of the higher prevalence of associated underlying infectious diseases.
PATIENT MANAGEMENT
A stepwise approach is useful for the clinical management of a patient with systemic
amyloidosis (Box 1).26 If amyloidosis is suspected, the first step is to obtain histologic
proof of amyloid, followed by a search for evidence of systemic amyloid deposition in
the patient. The next 2 steps are to determine the type of amyloid with confidence fol-
lowed by detection and (in AA and AL) quantification of the precursor protein in the
blood. A thoughtful clinical evaluation should lead to useful knowledge on the severity
of organ involvement, associated risks, prognosis, and an overview of all treatment
options. The most effective treatment of the underlying precursor-producing process
with acceptable risks and side effects should then be discussed with the patient. In the
final step, a proactive plan is made to evaluate the chosen treatment during follow-up.
In this plan, the effects of treatment must be monitored by assessing serum precursor
levels and the amyloid load of the body. Although the amyloid load of the body cannot
be measured directly, it is indirectly reflected by the function and size of affected
organs and by specific imaging techniques.
DETECTION OF AMYLOID
Detection of amyloid should start with a reasonable clinical suspicion of amyloidosis.
Clinical suspicion may increase on finding unexplained signs such as proteinuria,
organomegaly (liver, spleen, or tongue), right-sided cardiac failure and/or biventricular
hypertrophic cardiac walls, orthostatic hypotension, peripheral axonal polyneuropathy
or autonomic neuropathy (especially the combination of the 2), and malabsorption.4Box 1
Clinical management of a patient with systemic amyloidosis
Definite proof of amyloid in tissue
Convincing evidence for systemic amyloid deposition
Unequivocal characterization of the type of amyloid
Detection and/or quantification of the serum precursor protein
Assessment of clinical severity of organ and tissue involvement
Balanced choice of the most effective treatment with lowest risks
Planned monitoring of the effect of treatment during follow-up
Amyloidosis 329Sometimes, however, an alert pathologist performs a Congo Red stain after finding
eosinophilic material in a tissue biopsy even without any clinical suspicion of amyloid.
In that situation, the clinician has to deal with amyloid as a new and unsuspected
finding.
Amyloid is a tissue-based diagnosis. Therefore, the diagnosis of amyloid is based
on detecting its presence in tissue. The presence of amyloid is proved by a tissue
specimen showing positive for Congo Red stain and the characteristic apple-green
birefringence in polarized light (see Fig. 1). Subcutaneous abdominal fat tissue is
easily accessible for this purpose and a video of such a fat aspiration procedure is
available on the Web site at www.amyloid.nl.27 Ample fat tissue can also be obtained
by a simple surgical procedure.28 Fat tissue stained with Congo Red has high sensi-
tivity for AL, AA, and hereditary ATTR (up to 90%) and high specificity (almost 100%) if
stained properly and viewed by experienced observers using a high-quality micro-
scope with a good light source.29 Sensitivity of rectum tissue for these types is about
80% and about 60% for bone marrow in AL. Although a biopsy of the affected organ
(eg, kidney, liver, or heart) has the highest sensitivity (about 100%), it is recommended
to start with a biopsy of a clinically uninvolved site, such as fat tissue, rectum, bone
marrow, salivary gland, or gingiva, to avoid a biopsy of a vital organ and the associated
risk of serious bleeding. In wild-type ATTR amyloidosis, the sensitivity of fat tissue
analysis is a bit lower, about 73%.30
New staining methods for amyloid have been developed, such as luminescent
conjugated oligothiophenes (LCOs). The first results showed that these molecules
seem to bind to amyloid with higher sensitivity and greater selectivity than Congo
Red, as determined by fluorescence microscopy and light polarization microscopy.
Spectral profiles of tissue samples from 96 patients identified 3 nonoverlapping
classes, which were found to match AA, AL, and ATTR types.31 If these promising
data can be confirmed by other investigators, this new staining technique might
lead to improved detection of amyloid.
If amyloid has been found in a site specific for localized amyloidosis (genitourinary
tract, eyelid, conjunctiva, larynx, and so forth.) it is recommended to screen for
amyloid in another site of the body, such as fat tissue, rectum, bone marrow, or sali-
vary glands, before diagnosing localized amyloidosis. Systemic amyloidosis is diag-
nosed if amyloid is present in 2 different sites of the body. There is consensus that
systemic amyloidosis is also present if amyloid has been detected in only 1 site of
the body in combination with a classic picture of amyloidosis (Table 2) at an alternate
site.32TYPING OF AMYLOID WITH CONFIDENCE
After detection of amyloid, the specific type of amyloid should be characterized with
confidence. In most cases the type of amyloid can be assumed because of the
medical history and clinical picture. Nevertheless, even in patients with strong clinical
evidence for a particular type of amyloid, it is still necessary to search for solid
evidence of the specific type of amyloid involved because incorrect typing of amyloid
can have severe clinical consequences. The prognosis and treatment modalities differ
enormously among the 4 main types of systemic amyloidosis.
The usual method of typing amyloid is by immunohistochemistry of a biopsy sample
using specific antibodies. In AA amyloidosis, this technique is sufficient provided
sensitive and specific monoclonal antibodies are used. However, immunohistochem-
istry is less reliable in ATTR amyloidosis and is frequently even useless to demonstrate
AL amyloidosis.33,34 The absence of a positive family history does not exclude ATTR
Table 2
Organ involvement: positive biopsy at an alternate sitea and a positive organ criterion
Organ Criterion
Kidney 24-h urine protein >0.5 g/d, predominantly albumin
Heart Echo: mean wall thickness >12 mm, no other cardiac cause
Liver Total liver span >15 cm in the absence of heart failure or alkaline
phosphatase >1.5 times institutional upper limit of normal
Nerve Peripheral: clinical; symmetric lower extremity sensorimotor
peripheral neuropathy
Autonomic: gastric-emptying disorder, pseudoobstruction, voiding
dysfunction not related to direct organ infiltration
Gastrointestinal tract Direct biopsy verification with symptoms
Lung Direct biopsy verification with symptoms
Interstitial radiographic pattern
Soft tissue Tongue enlargement, clinical
Arthropathy
Claudication, presumed vascular amyloid
Skin
Myopathy by biopsy or pseudohypertrophy
Lymph node (may be localized)
Carpal tunnel syndrome
a Alternate sites available to confirm the histologic diagnosis of amyloidosis: fine-needle abdom-
inal fat aspirate and/or biopsy of the minor salivary glands, rectum, or gingiva.
Data from Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment
response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th Inter-
national Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Med
2005;79:319–28.
Hazenberg330amyloidosis, as demonstrated by several sporadic cases.16 Therefore, a TTRmutation
has to be confirmed by DNA analysis in ATTR amyloidosis. The exception to this rule is
wild-type ATTR amyloidosis in which, by definition, a TTR mutation is absent.
In patients with AL amyloidosis, an underlying monoclonal plasma cell dyscrasia
with overproduction of either lambda or kappa light chains can usually be detected
by investigating bone marrow (clonal dominance by immunophenotyping of plasma
cells), urine (Bence Jones proteins, immunofixation of concentrated urine), and blood
(M-protein, immunofixation, and, most important of all, by the free light chain assay).
Detection of a monoclonal gammopathy of undetermined significance does not
exclude other types than AL amyloidosis. The clinical pictures of ATTR amyloidosis
and AL amyloidosis are sometimes quite similar, for example, in cases with polyneur-
opathy, autonomic neuropathy, cardiomyopathy, or CTS. If such a clinical picture is
present, it is not sufficient to detect the presence of a plasma cell dyscrasia; it is
also necessary to exclude a TTR mutation before reliably concluding AL amyloid-
osis.16 In elderly men, the choice between wild-type ATTR and AL amyloidosis may
be hard to make if a slightly increased serum free light chain is detected in a patient
with cardiomyopathy as the sole disease manifestation.
New proteomics techniques have been developed to chemically analyze the protein
composition of tissues. The application of proteomics seems to be a promising tool for
reliable typing of amyloid.35–39 These techniques, with high sensitivity and high spec-
ificity, are especially helpful to distinguish between AL and ATTR amyloid. One of
these elegant techniques combines specific sampling by laser microdissection with
the analytical power of proteomic analysis based on tandem mass spectrometry.37
Amyloidosis 331However, currently these sophisticated, expensive, and time-consuming techniques
are only available in highly specialized centers, so for the time being immunohisto-
chemistry remains the standard procedure for typing of amyloid.40DISEASE MANIFESTATIONS
Although amyloidosis must have been present for a long time (often more than a year,
looking back to the start of the first symptoms), the disease goes unnoticed until
alarming symptoms appear relatively late in its course. Nonspecific complaints such
as fatigue and weight loss gradually appear and can be debilitating, but are often
noticed only after disease progression leads to more specific signs, such as edema,
dyspnea, bleeding, or orthostatic hypotension. A limited overview of the diverse
disease manifestations of the main types of amyloidosis4,7–10,24 is presented in this
section.
Renal disease is often seen in both AL and AA amyloidosis (in about 70%–90% of
cases) and rarely in ATTR amyloidosis. Sometimes the presentation is unremark-
able as asymptomatic proteinuria, but often it appears dramatically as frank
nephrotic syndrome or severe renal failure. The insidious nature of amyloidosis
keeps the disease unnoticed for a while until edema appears as a first sign of the
disease.
Edema, however, is also a presenting sign of cardiac disease. Signs and symptoms
of right-sided heart failure (edema, increased jugular venous pressure, third heart
sound, and hepatomegaly) are often seen. The clinical picture is that of a constrictive
cardiomyopathy, initially affecting the inflow of the heart more than the outflow. The
ejection fraction and cardiac size on the chest radiograph usually remain in the normal
range for a long time. Hypotension is often a prominent feature. Rapidly progressive
cardiac involvement is frequently part of the clinical picture of AL amyloidosis (in about
40%–60% of cases), whereas slowly progressive cardiomyopathy is usually seen in
ATTR amyloidosis. Cardiomyopathy is infrequent (about 5% of cases) in AA amyloid-
osis. A characteristic low-voltage pattern or a pseudoanteroseptal infarction pattern is
sometimes visible on the electrocardiogram. The combination of a low-voltage pattern
and thickened ventricular walls (left and right) on cardiac ultrasonography is pathogno-
monic for an infiltrative cardiomyopathy such as amyloidosis. Accumulation of amyloid
in the coronary arteries may lead to (often atypical) angina or infarction. Ventricular
tachycardia is a frequent and dangerous complication of AL amyloidosis. Conduction
disturbances are often seen in ATTR amyloidosis and can necessitate insertion of
a pacemaker in the long term. Increased serum N-terminal pro-brain natriuretic
peptide (NT-proBNP) and troponin-T concentrations can reveal asymptomatic cardiac
involvement and help to assess associated risks before the start of any treatment.41
Midregional proadrenomedullin (MR-proADM) seems to be a new and powerful prog-
nostic marker in AL amyloidosis, which may not only reflect cardiac dysfunction but
also widespread systemic disease, and can be combined with troponin-T to detect
patients at risk of early death.42
Hepatomegaly is rare in AA amyloidosis and is not seen in ATTR amyloidosis. It is
sometimes a presenting feature of AL amyloidosis, and the characteristic biochemical
profile of intrahepatic cholestasis shows an increase in g-glutamine transpeptidase,
followed by alkaline phosphatase and the bilirubin concentration. It is not always
easy to distinguish amyloid hepatomegaly from liver enlargement secondary to right-
sided cardiac failure. Splenomegaly is seen in about 5% of patients with AL amyloid-
osis and hyposplenism (identified by Howell-Jolly bodies or target cells) is present
in about 25%. Malabsorption, pseudoobstruction, ulceration, and gastrointestinal
Hazenberg332bleeding are infrequent but severe manifestations of bowel involvement. Gastropare-
sis, constipation, and diarrhea are more common and seem to be caused by auto-
nomic neuropathy. Sometimes the clinical picture is worsened by bacterial
overgrowth.
Peripheral sensory polyneuropathy, with ascending symptoms of numbness, pares-
thesia, and pain, is frequently observed in AL and ATTR amyloidosis but is extremely
rare in AA amyloidosis. Autonomic neuropathy is seen in all types of amyloidosis but is
most frequent and severe in AL and ATTR amyloidosis; it can lead to orthostatic hypo-
tension, impotence, bladder voiding disturbances, early sensation of fullness, nausea,
vomiting, diarrhea, and constipation.
Although CTS is a neuropathy of the median nerve and can therefore be part of
a generalized polyneuropathy, it is usually caused by entrapment caused by synovial
thickening through amyloid. CTS can be a manifestation of amyloid arthropathy (with
the characteristic shoulder-pad sign and pseudoarthritis of the small hand joints and
wrists) in AL and Ab2M amyloidosis. CTS is sometimes seen in wild-type ATTR
amyloidosis. A diversity of other manifestations may be present in AL amyloidosis,
such as waxy skin and skin nodules, easy bruising (vascular wall fragility), periorbital
purpura (raccoon eyes), coagulation abnormalities caused by Factor X deficiency (as
a result of increased removal by binding to amyloid), macroglossia (in about 20% of
cases) with indentations and submandibular swelling, dystrophic nails, taste distur-
bance, hoarseness, jaw claudication, musculopathy (pseudohypertrophy or muscular
dystrophy), bladder bleeding, lymphadenopathy, subclinical hypothyroidism, and
hypoadrenalism. Pulmonary amyloidosis is characterized by a reticulonodular pattern
on the chest radiograph and is rare. Pleural amyloidosis goes often undetected, but
becomes visible as rapidly progressive, relatively large, and diuretics-resistant pleural
effusions, usually during concomitant cardiac failure. Vitreous opacities may be
present, but only in ATTR amyloidosis in some of the TTR mutations. Central nervous
system involvement is unusual. Meningeal amyloidosis is only seen in some mutations
in ATTR amyloidosis. Involvement of the pituitary gland has been described, but is
rare.43–45 Ischemic stroke may be seen and is often caused by an embolism derived
from the affected heart.46IMAGING OF AMYLOIDOSIS
Amyloidoses are difficult diseases to diagnose. Their insidious appearance, the diverse
ways they present to manymedical specialists, the often severely affected organ func-
tion at diagnosis and the dangerous combinations of vital organs affected all demand
that the treating physician obtains a clear overview of the amyloid disease. The clini-
cian needs relevant information about the function and size of affected vital organs.
This information is essential both for diagnosis and for disease monitoring during
follow-up. Blood tests can be used to assess organ function, whereas imaging can
be used to assess size and function of organs. Ultrasonography of the abdomen, heart,
and musculoskeletal system, magnetic resonance imaging (MRI) of the heart, bone
scintigraphy, and SAP scintigraphy are all useful imaging techniques in selected cases.
Ultrasonography, computed tomography (CT), and MRI are well-known techniques
to evaluate the size of the kidneys, liver, and spleen. Musculoskeletal ultrasonography
is useful in Ab2M amyloidosis.
47 Cardiac ultrasonography is the method of choice to
quickly investigate the presence of myocardial sparkling, restriction to diastolic filling,
ejection fraction, and the thickness of the interventricular septum, left ventricular
posterior wall, and right ventricular wall. MRI of the heart can show global gadolinium
late enhancement in a subendocardial distribution that is highly sensitive and specific
Amyloidosis 333for the identification of cardiac involvement.48 [123I]metaiodobenzylguanidine may
help to detect cardiac sympathetic denervation.49 Aprotinin scintigraphy has been
used successfully for the identification of cardiac involvement in AL amyloidosis.50
A disadvantage of this tracer, however, is the potential infectious risk, because it is
a polypeptide derived from bovine lung tissue. Technetium Tc 99m pyrophosphate
and diphosphonate sometimes bind to amyloid and have been used as imaging
agents in amyloidosis, especially for detecting cardiac involvement in ATTR amyloid-
osis (Fig. 2).51,52 A similar tracer (3,3-diphosphono-1,2-propanodicarboxylic acid) has
also been shown to be useful for this purpose.53,54
SAP scintigraphy was developed in London by Hawkins and colleagues55 to detect
and identify the distribution of amyloid in systemic amyloidosis. SAPbinds in a calcium-
dependent way to all amyloid deposits. Scintigraphy with 123I-labeled SAP showsFig. 2. Technetium Tc 99m-methylene diphosphonate bone scintigraphy in a 31-year-old
man with ATTR amyloidosis. (A) Total body scan with increased cardiac uptake and soft
tissue uptake. The skeletal uptake is relatively diminished. (B) Coronal and (C) transverse
single photon emission-computed tomography/CT images of the heart showing increased
uptake in the ventricular walls.
Hazenberg334specific uptake in the liver, spleen, kidneys, adrenals, bone marrow, and joints
(Fig. 3).55–57 The heart cannot be visualized with this technique. Sensitivity of the
SAP scan for AL and AA amyloidosis is about 90%, but it is only 48% for hereditary
ATTR amyloidosis. Specificity is about 90%. SAP is isolated and purified from serum
of healthy donors and the potential infectious risk is probably the major reason why
this useful technique is currently being used only in the United Kingdom and The
Netherlands. Measurement of 123I SAP retention in the body after 24 or 48 hours
provides a rough quantitative estimate of the amyloid load in the patient.58,59 Recently,
an amyloid fibril–specific monoclonal antibody, 11-1F4, has shown promising results in
detecting AL amyloidosiswhen used as a tracer in positron emission tomography/CT.60
TREATMENT
The current basis for treatment is the so-called precursor-product concept. The
central idea of this concept is that further growth of amyloid deposits will stop when
the supply of necessary precursors is stopped. Thus, it is important to diagnose
amyloidosis early and start treatment as early as possible to stabilize the disease
and prevent ongoing progression.Fig. 3. Total body SAP scintigraphy (anterior and posterior images) of a 60-year-old woman
with systemic amyloidosis (probably AL type) with increased uptake (11) in the liver, spleen,
and kidneys and (1) bone marrow. Minor nonspecific uptake can be seen in the parotid
glands, nasopharynx and stomach.
Amyloidosis 335Treatment for AA amyloidosis is aimed at decreasing SAA serum levels to normal
basal values (<3 mg/L).8 If this level can be reached and maintained at less than
10 mg/L, the 10-year survival rate increases to 90%; when the SAA levels are more
than 10 mg/L, this figure is less than 40%.61 The only way to achieve a normal basal
serum value of SAA is by complete suppression or eradication of the underlying
chronic inflammatory disease. This can be realized in patients with infectious
diseases such as tuberculosis, leprosy, recurrent pulmonary infections, and osteomy-
elitis through eradication of the infection by antibiotic treatment sometimes combined
with surgery. The treatment of chronic inflammatory diseases such as rheumatoid
arthritis, ankylosing spondylitis, psoriatic arthritis, and Crohn disease has improved
dramatically in the last decades. Because of the introduction of more effective
antiinflammatory drugs such as methotrexate and biologics, especially those directed
against tumor necrosis factor (TNF) and interleukin-1 (IL-1), effective suppression of
SAA to low or even normal serum concentrations has become a realistic goal. In
addition, the autoinflammatory diseases such as FMF, TNF-receptor associated peri-
odic syndromes, the hyper-IgD syndrome, and cryopyrin-associated periodic
syndromes often respond well to some of these biologics, especially anakinra, which
is directed against IL-1.62 A promising new biologic is tocilizumab, an anti-IL6
receptor antibody that directly suppresses the production of C-reactive protein and
SAA by the liver.63
Treatment for AL amyloidosis is aimed at eradicating the underlying plasma cell
dyscrasia by chemotherapy, and return the abnormally increased level of kappa or
lambda free light chain in the blood to the normal range.64 High-dose melphalan
(HDM) followed by autologous stem cell transplantation (ASCT) in eligible patients
has shown considerable benefits.65 Median survival in this low-risk group, the ones
illegible for ASCT, was 4.6 years. However, 1 randomized clinical trial questioned
the favorable results of HDM followed by ASCT.66 Meanwhile, many more studies of
novel drugs, such as thalidomide, bortezomib, lenalidomide, pomalidomide, and
MLN9708, have shown clear effects, often with the best effects in combination with
dexamethasone.67 In a review by Gatt and Palladini,67 a state-of-the-art treatment
schedule is presented for low-risk, intermediate-risk and high-risk patients. The
survival of responding patients has increased and recent reports of patient cohorts
on long-term survival are encouraging. However, early deaths due to advanced,
irreversible cardiac dysfunction at presentation remain a huge unsolved problem.
Median survival of such untreated patients with advanced cardiac involvement is 3
to 6 months and does not really change with treatment. The debate concerning the
most effective and least dangerous treatment regimens will probably continue for
the next few years. The concept of striving for normalization of the free light chain
involved is still unchallenged and this normalization seems to result in actual regres-
sion of the amount of amyloid in tissue, as has been shown in fat tissue.68
Until recently, the only treatment for patients with hereditary ATTR amyloidosis was
liver transplantation with the aim of removing the source of 99% of the mutated TTR in
the circulation.69 However, this approach is not always successful because ATTR
amyloid sometimes progresses in the heart after liver transplantation (Fig. 4). For
this reason, patients with late disease onset (often men with cardiomyopathy) and
non–TTR-Met30 mutations are less suitable for liver transplantation.69,70 The amyloid
fibril composition also seems to predict progressive cardiomyopathy after liver trans-
plantation.71 The 10-year survival of the TTR-Met30 patients after liver transplantation
is currently about 85%.69
In Ab2M amyloidosis, high-flux membranes and adsorption columns have been
studied in hemodialysis in an attempt to lower the b2M serum concentrations. Kidney
Fig. 4. A 51-year-old woman with hereditary ATTR amyloidosis who received a liver trans-
plant (Liver Tx) 2 years after diagnosis. Progressive cardiomyopathy reflected by an increase
of NT-proBNP (black circles), mean left ventricular wall size (black diamonds), and right
ventricular wall size (white diamonds). The dotted lines represent the upper limits of the
right ventricular wall diameter (5 mm) and left ventricular wall diameter (12 mm).
Hazenberg336transplantation, however, remains the treatment of choice. After transplantation, the
amyloidosis seems to stabilize; the b2M serum levels decrease to normal, bone pain
and stiffness decrease, the cystic lesions do not increase further in size, but regression
of amyloid deposits has not been reported.72
Apart from treating the underlying precursor-producing process, it is also important
to provide supportive treatment for decreased organ function caused by amyloid
deposition. Involvement of more than 1 vital organ frequently results in a mixture of
serious problems. It is often difficult and sometimes impossible to find an acceptable
solution for all problems. To get the best results of supportive treatment for the indi-
vidual patient with amyloidosis, it is necessary that all medical specialists involved
collaborate closely and that 1 specialist coordinates the collective efforts.DISEASE MONITORING
Maintaining a good overview of the effect of treatment is important for such an intan-
gible disease as systemic amyloidosis. The accumulation of amyloid is expected to
stop after successful elimination of the precursor supply and the tissue itself tries to
remove amyloid. Repeated measurements are useful to monitor the effect (or lack
of effect) of treatment. Two different processes need to be monitored (Box 2).
The first process is that of the underlying production of the precursor proteins SAA,
free kappa or lambda light chain, and (mutated) TTR in AA, AL, and ATTR amyloidosis,
respectively. After successful treatment, the SAA levels should decrease and remain
Box 2
Monitoring of systemic amyloidosis during follow-up using a set of core data. Not all items are
always indicated; the choice depends on type of amyloid and patient characteristics
Frequent (3–6 times per year):
Precursor SAA and CRP (AA)
Kappa or lambda free light chain, M-protein, Bence Jones in urine (AL)
Serum Urea, creatinine, albumin
Total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase
N-terminal pro-brain natriuretic peptide, troponin-T
Urine Endogenous creatinine clearance
Protein/24 h, protein/creatinine ratio
Infrequent (once per year, two years, or if indicated):
Precursor Bone marrow biopsy (AL) to verify complete response or suspicion of relapse
Imaging Echocardiography (ventricular wall thicknesses, ejection fraction)
Abdominal echography (sizes of liver, spleen, and kidneys)
Diphosphonate scintigraphy (ATTR)
SAP scintigraphy (AA and AL)
Function ECG, Holter monitoring for 24 h
Tissue Amyloid grade (or amyloid protein concentration) in subcutaneous fat tissue
Amyloidosis 337at less than 3 mg/L continuously, the free kappa and lambda levels and the kappa/
lambda ratio should definitely decrease within the reference ranges, and mutant
TTR should no longer be detectable in the blood.
The second process is that of amyloid accumulation, the so-called clinical amyloid
load. Quantitative clinical abnormalities are available for monitoring this clinical amyloid
load, such as serum albumin, alkaline phosphatase, bilirubin, NT-proBNP, troponin,
creatinine clearance, proteinuria, ventricular wall thickness, ejection fraction, conduc-
tion and rhythm, heart rate variability, Ewing battery results of autonomic function, and
the sizes of enlarged organs, such as the liver, spleen, and kidneys. Imaging techniques
and subcutaneous fat tissue samples can be used for monitoring (Fig. 5). At
a consensus meeting in Tours in 2004, a set of response criteria for systemic AL
amyloidosiswas acceptedby the international amyloidosis community,32with the addi-
tion of some modifications after the last consensus meeting in Groningen in 2012.67CURRENT PERSPECTIVES
The precursor-product concept helps in understanding why the current treatment
aimed at normalization of the precursor protein is important to prevent further accu-
mulation of amyloid. New developments in this area include antisense73 and RNAi74
treatment. Both treatments suppress TTR production by the liver resulting in low
TTR serum concentrations. Most of the current research, however, has changed its
focus to the development of new drugs to stabilize precursor proteins, interfere with
amyloid deposition, or stimulate amyloid removal.
New drugs are under investigation for ATTR amyloidosis, such as diflunisal and tafa-
midis, that stabilize the conformation of TTR in the circulation and interfere with depo-
sition of amyloid. Both diflunisal and tafamidis stabilize the TTR tetramer in blood
in vitro and inhibit the tetramer in breaking up into amyloidogenic dimers and mono-
mers.75 A clinical trial of tafamidis has recently been published and shows an inhibitory
effect on the progression of polyneuropathy in patients with ATTR amyloidosis.76 A
clinical trial of diflunisal comprising 130 patients was completed at the end of 2012,
so the results are expected soon.77 A study of doxycyclin in combination with
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=Amyloidosis 339tauroursodeoxycholic acid, a biliary acid, in mice showed that this combination was
capable of stimulating removal of ATTR amyloid deposits.78 A phase II study of this
drug combination has been started in patients with ATTR amyloidosis.79
Eprodisate, another promising drug, has shown an inhibitory effect on the progres-
sion of kidney disease in patients with AA amyloidosis in a first clinical trial.80 This drug
interferes with the binding of SAA to glycosaminoglycans in tissue.81 Although the
magnitude of the clinical effects of tafamidis in ATTR amyloidosis and eprodisate in
AA amyloidosis is moderate, the real relevance of both studies is that they show proof
of concept that interference with the formation and deposition of amyloid is a realistic
goal. Epigallocatechin-3-gallate (EGCG), a green tea extract, seems to have an inhib-
itory effect on the formation of AL and ATTR amyloid.82–84 A clinical trial has started to
evaluate a possible role of EGCG in promoting regression of residual cardiac damage
in patients with AL amyloidosis who have successfully completed chemotherapy.67
An interesting development is the combined use of a drug called CPHPC and anti-
SAP antibodies. CPHPC (the abbreviation of (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-
6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid) is a drug that effectively depletes SAP
from the circulation.85 This mechanism possibly stops accumulation of amyloid and
may be useful for all types of systemic amyloidosis, although fibrinogen-derived
amyloidosis seems to respond best.86 Vaccination against amyloid has been attemp-
ted in the past with poor results. Early vaccination research was primarily focused on
the induction of antibodies against conformational epitopes that were believed to be
present in all types of amyloid.87 The Royal Free group in London recently demon-
strated that CPHPC followed by anti-SAP antibodies resulted in a quick removal of
almost all AA amyloid from the tissues in mice with AA amyloidosis.88 If this dramatic
effect on amyloid can be replicated in humans, it may lead to a major change in the
prognosis for patients with all types of systemic amyloidosis.
HEALTHY AGING AND PROTEIN MISFOLDING
Autopsy data suggest that supercentenarians (110 years or older) die in about 70% of
cases from ATTR amyloidosis-related causes.89 Neurodegenerative diseases such as
Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and Huntington
disease, in all of which protein misfolding is a prominent feature, emerge with aging.
The induction of aggregation involves a crystallizationlike seeding mechanism by
which a specific protein is structurally corrupted by its misfolded conformer.90 Seed-
ing is also described in other forms of amyloidosis and, although the clinical conse-
quences do not seem to be prominent, this prionlike behavior is an aspect of theseFig. 5. A 62-year-old woman with systemic AL kappa amyloidosis associated with multiple
myeloma. She was treated with HDM followed by ASCT. (A) Follow-up of serum concentra-
tions of alkaline phosphatase (AP), g-glutamyl transpeptidase (GGT), NT-proBNP, and the
kappa free light chain. The bottom part shows the semiquantitative grading of amyloid in
fat tissue (ranging from 0 to 41). Dotted lines display the upper limit of the reference control
values. (B) Follow-up of SAP scintigraphy (anterior view) at the start of treatment and 1, 3, and
6 years thereafter. At the start, intensive uptake in an enlarged liver (111), spleen (111) and
in bone marrow (11) is visible. After 1 year, diminished bone marrow and splenic uptake (1)
is visible and the liver uptake has become normal except for a small upper segment of the
right lobe. After 3 and 6 years, some splenic uptake persists (1), the localized liver uptake
diminishes slowly, and the bone marrow uptake has disappeared. Some nonspecific uptake
or excretion can be seen in thyroid, stomach, and bladder (and minimal extravasation of
blood or tracer at the injection site near the left elbow after 1 and 3 years).
Hazenberg340protein-misfolding diseases that certainly deserves serious attention.91,92 In common
cardiac diseases, such as pathologic cardiac hypertrophy and dilated and ischemic
cardiomyopathies, misfolded proteins have a direct causative role.93 Protein misfold-
ing is not only a characteristic of some obscure amyloid diseases but is a much
broader phenomenon that is involved in many other degenerative diseases closely
associated with aging.94 Therefore, a better understanding of the nature and patho-
genesis of all types of amyloidosis may also increase our knowledge of these common
and disabling degenerative diseases that interfere so much with healthy aging.
ACHIEVEMENTS
The amyloidoses are fascinating representatives of a new disease category of protein-
misfolding diseases. Hundred years ago it was a mystery why so different diseases as
multiple myeloma and tuberculosis could end up with organs massively filled with
apparently similar amyloid. Often, however, amyloidosis appeared in a patient without
any clear cause, and was therefore thought to be primary. Occasionally the disease
was found in succeeding generations of a family. But diagnostic possibilities improved
steadily. The iodine sulphuric staining test was replaced by metachromatic stains,
such as Congo red, in order to better identify amyloid in tissue. It was the introduction
of biopsies that enabled clinicians to diagnose amyloid during life, although biopsies
were used restrictively until the mid twentieth century. But the major breakthrough
came with the work of Pras in 1968, who succeeded in isolating amyloid fibrils by
extraction with distilled water.95 Since that time the amyloid protein became acces-
sible for chemical analysis. The amyloid proteins were chemically characterized,
amyloid precursor proteins were detected in blood, and many DNA mutations were
connected to familial types of amyloidosis.
The current classification of amyloidosis is in a way a monument of the recent
analytical and clinical research. Nowadays a patient suffering from systemic amyloid-
osis can be diagnosed and typed rapidly with minimal discomfort. The patient
undergoes a clinical assessment consisting of blood analyses, function tests, and
imaging techniques that yields a quick overview of the severity of organ disease
and associated risks. Treatment possibilities range widely from several biologic
modifiers, novel cytostatic drugs, or drugs specifically designed for amyloidosis to
transplantation of liver or bone marrow. Monitoring the effects of treatment during
follow-up has improved and enables the clinician to assess early whether or not the
amyloidosis responds to the chosen treatment.
CURRENT CHALLENGES
Despite these favorable developments, however, the prognosis remains grim for many
patients suffering from systemic amyloidosis. The reasons are manifold, but the
current main challenges are lack of awareness and loss of precious time in waiting
for - often ineffective - precursor elimination.
Lack of awareness leads to late detection and far advanced disease at presentation,
often severe cardiac disease or multi-organ disease. Doctors should think of amyloid-
osis - or their computers should suggest it - if key symptoms for the diagnosis are
present. This is especially true if more symptoms than one are present. Typical key
symptoms are right sided cardiac failure, proteinuria or renal failure, organ swelling
(of tongue, myocardium, liver, or spleen), polyneuropathy, or autonomic neuropathy
that are all unaccounted for. In many such cases looking for an elevated serum free
light chain and performing an abdominal fat aspiration may speed up the diagnosis
by months.
Amyloidosis 341Waiting until the precursor has decreased to normal levels is sometimes impossible,
because the disease progresses meanwhile. Many patients with severe cardiac AL
amyloidosis have not had any profit of improved treatment, because they die from
disease progression in the first months after diagnosis. And even sometimes the
amyloidosis progresses despite successful reduction or even elimination of the
precursor. This is frequently observed in some types of ATTR amyloidosis after liver
transplantation, because wild-type TTR becomes deposited in the heart instead of
mutant TTR. There is a need for reliable methods to measure the actual production
and deposition of amyloid. And treatment tools need to be developed that stop
amyloid deposition immediately after detection as well as additional tools that effec-
tively help to remove amyloid from the body. So, although much has been achieved
in the last fifty years, there is much left for fundamental and clinical researchers to
improve the prospects of patients suffering from these deadly, but also fascinating
amyloid diseases.
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